Credit Suisse analyst Martin Auster upgraded Spark Therapeutics (NASDAQ: ONCE) from Underperform to Neutral with a price target of $44.00 ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE